Ravulizumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Ravulizumab
- Ravulizumab: From Complement-Mediated Hemolytic Disorders to Congenital Neutropenia (G6PC3 Deficiency)
Ravulizumab: From Complement-Mediated Hemolytic Disorders to Congenital Neutropenia (G6PC3 Deficiency)
One-Sentence Summary
Ravulizumab is a long-acting anti-C5 monoclonal antibody whose established clinical role, per the repurposing rationale on file, is treating complement-mediated hemolytic and thrombotic microangiopathic disorders such as PNH and aHUS. The TxGNN model predicts it may be effective for autosomal recessive severe congenital neutropenia due to G6PC3 deficiency, but currently 0 clinical trials and 0 publications support this direction — the model itself flags the mechanistic link as weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in structured regulatory data (0 EU authorizations on file); rationale text indicates established use in complement-mediated hemolysis/TMA (e.g., PNH, aHUS) |
| Predicted New Indication | Autosomal Recessive Severe Congenital Neutropenia due to G6PC3 Deficiency |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is flagged as a data gap in the evidence pack (DG002). However, the repurposing rationale field describes Ravulizumab as a long-acting anti-C5 monoclonal antibody that blocks formation of the terminal complement complex (membrane attack complex, MAC), with clinical relevance concentrated in complement-mediated hemolysis and thrombotic microangiopathy — conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
The predicted new indication, G6PC3-deficient severe congenital neutropenia, is driven by endoplasmic-reticulum stress that increases neutrophil apoptosis — a glucose-metabolism and ER-function disorder. This pathway does not overlap with terminal complement activation.
The rationale supplied with this candidate explicitly states the mechanistic link is weak, and suggests the prediction may reflect the knowledge graph clustering rare hematologic diseases together rather than a genuine shared biological pathway. This is a case where a high TxGNN score is not corroborated by any independent mechanistic or clinical signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorizations are on file for Ravulizumab in this dataset (market status: Not Marketed, 0 authorizations).
Safety Considerations
Please refer to the SmPC for safety information.
(Note: Safety warnings, contraindications, and DDI data are marked as a blocking data gap (DG001) in this evidence pack and could not be evaluated.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN model score (L5, no clinical trials or literature), and the rationale itself identifies the drug-disease mechanistic link as weak/likely noise. Combined with a blocking data gap on safety labeling, this candidate does not meet the threshold to advance past S0.
To proceed, the following is needed:
- Confirmed mechanism-of-action data for Ravulizumab (resolve DG002)
- TFDA/SmPC-equivalent safety labeling — warnings, contraindications, DDI (resolve DG001, blocking)
- Independent mechanistic or preclinical evidence linking terminal complement inhibition to G6PC3-deficient neutropenia
- Confirmation of current EU regulatory/marketing status, since this dataset shows 0 authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.